Effects of ellagic acid on angiogenic factors in prostate cancer cells

Cancers

Volumn 5, Issue 2, 2013, Pages 726-738

  Vanella, Luca ^a   Di Giacomo, Claudia ^a   Acquaviva, Rosaria ^a   Barbagallo, Ignazio ^a   Li Volti, Giovanni ^a   Cardile, Venera ^a   Abraham, Nader G ^b   Sorrenti, Valeria ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Cytochrome P450; Heme oxygenase; Prostate cancer

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ANGIOGENIC FACTOR; CYTOCHROME P450; CYTOCHROME P450 2J2; ELLAGIC ACID; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; FIBROBLAST GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; HEME OXYGENASE; HEME OXYGENASE 1; HEME OXYGENASE 2; INTERLEUKIN 15; MESSENGER RNA; OSTEOPROTEGERIN; SCATTER FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; METASTASIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUPERNATANT; TUMOR REGRESSION; WESTERN BLOTTING;

EID: 84881386679     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers5020726     Document Type: Article

References (75)

1. Ferlay, J.; Parkin, D.M.; Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46, 765-781.
2. Imamoto, T.; Suzuki, H.; Akakura, K.; Komiya, A.; Nakamachi, H.; Ichikawa, T.; Igarashi, T.; Ito, H. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr. J. 2001, 48, 573-578.
3. Syed, D.N.; Khan, N.; Afaq, F.; Mukhtar, H. Chemoprevention of prostate cancer through dietary agents: Progress and promise. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 2193-2203.
4. Khan, N.; Afaq, F.; Mukhtar, H. Cancer chemoprevention through dietary antioxidants: Progress and promise. Antioxid. Redox Signal. 2008, 10, 475-510.
5. Kaplan, M.; Hayek, T.; Raz, A.; Coleman, R.; Dornfield, L.; Vaya, J.; Aviram, M. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J. Nutr. 2001, 131, 2082-2089.
6. Kim, N.D.; Mehta, R.; Yu, W.; Neeman, I.; Livney, T.; Amichay, A.; Poirier, D.; Nicholls, P.; Kirby, A.Jiang, W.; et al; Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res. Treat. 2002, 71, 203-217.
7. Cerda, B.; Llorach, R.; Ceron, J.J.; Espin, J.C.; Tomas-Barberan F.A.Evaluation of the bioavailability and metabolism in the rat of punicalagin.; an antioxidant polyphenol from pomegranate juice. Eur. J. Nutr. 2003, 42, 18-28.
8. Narayanan, B.A.; Geoffrey, O.; Willingham, M.C.; Re, G.G.; Nixon, D.W. p53/p21 (WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett. 1999, 136, 215-221.
9. Khanduja, K.L.; Gandhi, R.K.; Pathania, V. Syanl NPrevention of N-nitrosodiethylamine-induced lung tumorigenesis by ellagic acid and quercetin in mice. Food Chem. Toxicol. 1999, 37, 313-318.
10. Mertens-Talcott, S.U.; Talcott S.T.; Percival, S.S. Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 human leukemia cells. J. Nutr. 2003, 133, 2669-2674.
11. Heber, D. Multitargeted therapy of cancer by ellagitannins. Cancer Lett. 2008, 269, 262-268.
12. Seeram, N.P.; Adams, L.S.; Henning, S.M.; Niua, Y.; Zhang, Y.; Nair, M.G.; Heber, D. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J. Nutr. Biochem. 2005, 16, 360-367.
13. Seeram, N.P.; Aronson, W.J.; Zhang, Y.; Henning, S.M.; Moro, A.; Lee R.P.; Sartippour, M.; Harris D.M.; Rettig, M.B.; Suchard, M.A.; et al. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J. Agric. Food Chem. 2007, 55, 7732-7737.
14. Falsaperla, M.; Morgia, G.; Tartarone, A.; Ardito, R.; Romano, G.; Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur. Urol. 2005, 47, 449-455.
15. Lansky, E.P.; Harrison, G.; Froom, P.; Jiang, W.G. Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel TM. Invest. New Drugs 2005, 23, 121-122.
16. Sartippour, M.; Seeram, N.P.; Rao, J.Y.; Moro, A.; Harris, D.M.; Henning, S.M.; Firouzi, A.; Rettig, M.B.; Aronson, W.J. Pantuck A.J.;et al.; Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int. J. Oncol. 2008, 32, 475-480.
17. Umesalma, S.; Sudhandiran, G. Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. Eur. J. Pharmacol. 2011, 660, 249-258.
18. Larrosa, M.; Tomás-Barberán, F.A.; Espín, J.C. The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J. Nutr. Biochem. 2006, 17, 611-625.
19. Li, T.M.; Chen, G.W.; Su, C.C.; Lin, J.G.; Yeh, C.C.; Cheng, K.C.; Chung, J.G. Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res. 2005, 25, 971-979.
20. Losso, J.N.; Bansode, R.R.; Trappey, A., II; Bawadi, H.A.; Truax, R. In vitro antiproliferative activities of ellagic acid. J. Nutr. Biochem. 2004, 15, 672-678.
21. Vanella, L.; Barbagallo, I.; Acquaviva, R.; di Giacomo, C.; Cardile, V.; Abraham, N.G.; Sorrenti, V. Ellagic acid: Cytodifferentiating and antiproliferative effects in human prostatic cancer cell lines. Curr. Pharm. Design 2013, 19, 2728-2736.
22. Tuli, S.Predictors of survival in patients with prostate cancer and spinal metastasis. J. Neurosurg. 2010, 13, 789-794.
23. Nayyar, R.; Sharma, N.; Gupta, N.P. Prognostic factors affecting progression and survival in metastatic prostate cancer. Urol. Int. 2010, 84, 159-163.
24. Yigitbasi, O.; Ozturk, U.; Goktug, H.N.; Gucuk, A.; Bakirtas, H. Prognostic factors in metastatic prostate cancer. Urol. Oncol. 2011, 29, 162-165.
25. Liotta, L.A.; Steeg, P.S.; Stetler-Stevenson, W.G. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1999, 64,327-336.
26. Fidler, I.J.; Ellis, L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994, 79, 185-188.
27. Folkman, J.Clinical applications of research on angiogenesis. N. Engl J. Med.1995, 333, 1757-1763.
28. Weidner, N.; Carroll, P.R.; Flax, J.; Blumenfeld, W.; Folkman, J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 1993, 143, 401-409.
29. Vanella, L.; di Giacomo, C.; Acquaviva, R.; Santangelo, R.; Cardile, V.; Barbagallo, I.; Abraham, N.G.; Sorrenti, V. The DDAH/NOS pathway in human prostatic cancer cell lines: antiangiogenic effect of L-NAME. Int. J. Oncol. 2011, 39, 1303-1310.
30. Bhat, T.A.; Singh, R.P. Tumor angiogenesis-A potential target in cancer chemoprevention.Food Chem. Toxicol. 2008, 46, 1334-1345.
31. Kawanishi, K.; Ueda, H.; Moriyasu, M. Aldose reductase inhibitors from the nature. Curr. Med. Chem. 2003, 10, 1353-1374.
32. Labrecque, L.; Lamy, S.; Chapus, A.; Mihoubi, S.; Durocher, Y.; Cass, B.; Bojanowski, M.W.; Gingras, D.; Béliveau, R. Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis 2005, 26, 821-826.
33. Wang, N.; Wang, Z.Y.; Mo, S.L.; Loo, T.Y.; Wang, D.M.; Luo, H.B.; Yang, D.P.; Chen, Y.L.; Shen, J.G.; Chen, J.P. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast Cancer Res. Treat. 2012, 134, 943-955.
34. Zenclussen, A.C.; Lim, E.; Knoeller, S.; Knackstedt, M.; Hertwig, K.; Hagen, E.; Klapp, B.F.; Arck, P.C. Heme oxygenases in pregnancy II: HO-2 is downregulated in human pathologic pregnancies. Am. J. Reprod. Immunol. 2003, 50, 66-76.
35. Li Volti, G.; Sacerdoti, D.; Sangras, B.; Vanella, A.; Mezentsev, A.; Scapagnini, G.; Falck, J.R.; Abraham, N.G. Carbon monoxide signaling in promoting angiogenesis in human microvessel endothelial cells. Antioxid. Redox Signal. 2005, 7, 704-710.
36. Sunamura, M.; Duda, D.G.; Ghattas, M.H.; Lozonschi, L.; Motoi, F.; Yamauchi, J.; Matsuno, S.; Shibahara, S.; Abraham, N.G. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 2003, 6, 15-24.
37. Botros, F.T.; Schwartzman, M.L.; Stier, C.T.; Goodman, A.I.; Abraham, N.G. Increase in heme oxygenase-1 levels ameliorates renovascular hypertension. Kidney Int. 2005, 68, 2745-2755.
38. Yu, W.; Chen, L.; Yang, Y.Q.; Falck, J.R.; Guo, A.M.; Li, Y.; Yang, J. Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer. Cancer Chemother. Pharmacol. 2011, 68, 619-629.
39. Nithipatikom, K.; Isbell, M.A.; See, W.A.; Campbell, W.B. Elevated 12- and 20-hydroxyeicosatetraenoic acidin urine of patients with prostatic diseases. Cancer Lett. 2006, 233, 219-225.
40. Kuttan, G.; Pratheeshkumar, P.; Manu, K.A.; Kuttan, R. Inhibition of tumor progression by naturally occurring terpenoids. Pharm. Biol. 2011, 49, 995-1007.
41. Pratheeshkumar, P.; Sreekala, C.; Zhang, Z.; Budhraja, A.; Ding, S.; Son, Y.O.; Wang, X.; Hitron, A.; Hyun-Jung, K.; Wang, L.; et al. Cancer prevention with promising natural products: Mechanisms of action and molecular targets. Anticancer Agents Med. Chem. 2012, 12, 1159-1184.
42. Kang, N.J.; Shin, S.H.; Lee, H.J.; Lee, K.W. Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis. Pharmacol. Therapeut. 2011, 130, 310-324.
43. Weng, C.J.Yen, G.C.; Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: Phenolic acids, monophenol, polyphenol, and their derivatives. Pharmacol. Therapeut. 2012, 38, 76-87.
44. Malik, A.; Afaq, F.; Sarfaraz, S.;Adhami, V.M.; Syed, D.N.Mukhtar H.; Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 14813-14818.
45. Dvorak, H. Angiogenesis: Update 2005. J. Thromb. Haemost. 2005, 3, 1835-1842.
46. Roberts, W.G.; Palade, G.E. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res. 1997, 57, 765-772.
47. Turner, N.; Grose, R. Fibroblast growth factor signalling: From development to cancer. Nat. Rev. Cancer 2010, 10, 116-129.
48. Varkaris, A.; Corn, P.G.; Gaur, S.; Dayyani, F.; Logothetis, C.J.; Gallick, G.E. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin. Investig. Drugs 2011, 20, 1677-1684.
49. Matsuoka, Y.; Arai, G.; Okada, Y.; Aida, J. Prostate cancer-producing granulocyte colony-stimulating factor. Urol. Int. 2009, 82, 113-115.
50. Mengus, C.; le Magnen, C.; Trella, E.; Yousef, K.; Bubendorf, L.; Provenzano, M.; Bachmann, A.; Heberer, M.; Spagnoli, G.C.; Wyler, S. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J. Transl. Med. 2011, 9, 162.
51. Brown, J.M.; Corey, E.; Lee, Z.D.; True, L.D.; Yun, T.J.; Tondravi, M.; Vessella, R.L. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001, 57, 611-616.
52. Tozawa, K.; Yamada, Y.; Kawai, N.; Okamura, T.; Ueda, K. Kohri, K.; Osteopontin expression in prostate cancer and benign prostatic hyperplasia. Urol. Int. 1999, 62, 155-158.
53. Kamiya, N.; Suzuki, H.; Endo, T.; Takano, M.; Yano, M.; Naoi, M.; Kawamura, K.; Imamoto, T.; Takanami, M.; Ichikawa T., Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis. Int. J. Clin. Oncol. 2011, 16, 366-372.
54. Abraham, N.G.; Kappas, A.Pharmacological and clinical aspects of heme oxygenase Pharmacol. Rev. 2008, 60, 79-127.
55. Bussolati, B.; Mason, J.C. Dual role of VEGF-induced heme-oxygenase-1 in angiogenesis. Antioxid. Redox Signal. 2006, 8, 1153-1163.
56. Alaoui-Jamali, M.A.; Bismar, T.A.; Gupta, A.; Szarek W.A.; Su, J.; Song, W.; Xu, Y.; Xu, B.; Liu, G.Vlahakis, J.Z.; et al; A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009, 69, 8017-8024.
57. He, J.Z.; Ho, J.J.; Gingerich, S.; Courtman, D.W.; Marsden, P.A.; Ward, M.E. Enhanced translation of heme oxygenase-2 preserves human endothelial cell viability during hypoxia. J. Biol. Chem. 2010, 285, 9452-9461.
58. Burgess, A.P.; Vanella, L.; Bellner, L.; Gotlinger, K.; Falck, J.R.; Abraham, N.G.; Schwartzman, M.L.; Kappas, A. Heme oxygenase (HO-1) rescue of adipocyte dysfunction in HO-2 deficient mice via recruitment of epoxyeicosatrienoic acids (EETs) and adiponectin. Cell. Physiol. Biochem. 2012, 29, 99-110.
59. Sodhi, K.; Inoue, K.; Gotlinger, K.H.; Canestraro, M.; Vanella, L.; Kim, D.H.; Manthati, V.L.; Koduru, S.R.; Falck, J.R.Schwartzman M.L.et al.; Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J. Pharmacol. Exp. Ther. 2009, 331, 906-916.
60. Patel, M.I.; Kurek, C.; Dong, Q. The arachidonic acid pathway and its role in prostate cancer development and progression. J. Urol. 2008, 179, 1668-1675.
61. Panigrahy, D.; Greene, E.R.; Pozzi, A.; Wang, D.W.; Zeldin, D.C. EET signaling in cancer. Cancer Metast. Rev. 2011, 30, 525-540.
62. Zeldin, D.C. Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem. 2001, 276, 36059-36062.
63. Suzuki, S.; Oguro, A.; Osada-Oka, M.; Funae, Y.; Imaoka, S. Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells. J. Pharmacol. Sci. 2008, 108, 79-88.
64. Webler, A.C.; Michaelis, U.R.; Popp, R.; Barbosa-Sicard, E.; Murugan, A.; Falck, J.R.; Fisslthaler, B.; Fleming, I. Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. Am. J. Physiol. Cell Physiol. 2008, 295, C1292-C1301.
65. Yang, S.; Wei, S.; Pozzi, A.; Capdevila, J.H. The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. Arch. Biochem. Biophys. 2009, 489, 82-91.
66. Chen, C.; Wei, X.; Rao, X.; Wu, J.; Yang, S.; Chen, F.; Ma, D.; Zhou, J.; Dackor, R.T.; Zeldin, D.C.; et al.Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. J. Pharmacol. Exp. Ther. 2011, 336, 344-355.
67. Jiang, J.G.; Ning, Y.G.; Chen, C.; Ma, D.; Liu, Z.J.; Yang, S.; Zhou, J.; Xiao, X.; Zhang, X.A.; Edin, M.L.; et al. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res. 2007, 67, 6665-6674.
68. Pozzi, A.; Macias-Perez, I.; Abair, T.; Wei, S.; Su, Y.; Zent, R.; Falck J.R.; Capdevila, J.H. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J. Biol. Chem. 2005, 280, 27138-27146.
69. Wang, Y.; Wei, X.; Xiao, X.; Hui, R.; Card, J.W.; Carey, M.A.; Wang, D.W.; Zeldin, D.C. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J. Pharmacol. Exp. Ther. 2005, 314, 522-532.
70. Nithipatikom, K.; Brody, D.M.; Tang, A.T.; Manthati, V.L.; Falck, J.R.; Williams, C.L.; Campbell, W.B. Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists Cancer Sci. 2010, 101, 2629-2636.
71. Lin, J.; Haffner, M.C.; Zhang, Y.; Lee, B.H.; Brennen, W.N.; Britton, J.; Kachhap, S.K.; Shim, J.S.; Liu, J.O.Nelson, W.G.;et al;.Disulfiram is a dna demethylating agent and inhibits prostate cancer cell growth. Prostate 2011, 71, 333-343.
72. Zhang, D.; Ai, D.; Tanaka, H.; Hammock, B.D.; Zhu, Y. DNA methylation of the promoter of soluble epoxide hydrolase silences its expression by an SP-1-dependent mechanism. Biochim. Biophys. Acta 2010, 1799, 659-667.
73. Guo, A.M.; Arbab, A.S.; Falck, J.R.; Chen, P.; Edwards, P.A.; Roman, R.J.; Scicli, A.G. Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J. Pharmacol. Exp. Ther. 2007, 321, 18-27.
74. Chen, L.; Ackerman, R.; Guo, A.M. 20-HETE in neovascularization. Prostag. Other Lipid Mediat. 2012, 98, 63-68.
75. Alexanian, A.; Rufanova, V.A.; Miller, B.; Flasch, A.; Roman, R.J.; Sorokin, A. Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth. Anticancer Res. 2009, 29, 3819-3824.